Novel aspects of corneal angiogenic and lymphangiogenic privilege

Progress in Retinal and Eye Research

Volumn 29, Issue 3, 2010, Pages 208-248

  Ellenberg, David ^a   Azar, Dimitri T ^a   Hallak, Joelle A ^a   Tobaigy, Faisal ^b   Han, Kyu Yeon ^a   Jain, Sandeep ^a   Zhou, Zhongjun ^c   Chang, Jin Hong ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; ANGIOSTATIN; ANTIINFECTIVE AGENT; BASIC FIBROBLAST GROWTH FACTOR; BEVACIZUMAB; CANSTATIN; CYCLOOXYGENASE 2; DECORIN; DEXAMETHASONE; ENDOSTATIN; ENDOTHELIN 1; EPHRIN; EPHRIN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIGALLOCATECHIN GALLATE; GELATINASE A; GELATINASE B; HYDROCORTISONE; MATRIX METALLOPROTEINASE 14; NONSTEROID ANTIINFLAMMATORY AGENT; PIGMENT EPITHELIUM DERIVED FACTOR; PROPOLIS; RANIBIZUMAB; RESTIN; RESVERATROL; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 3; VITAMIN D;

ACANTHAMOEBA KERATITIS; ANGIOGENESIS; BLINDNESS; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL FEATURE; CORNEA LIMBUS; CORNEA NEOVASCULARIZATION; CORNEA STROMA; CORNEA TRANSPLANTATION; CORNEA VASCULARIZATION; DOWN REGULATION; GENETIC ASSOCIATION; HUMAN; IMMUNOHISTOCHEMISTRY; INJURY; KERATITIS; KERATOPLASTY; LYMPHANGIOGENESIS; MACROPHAGE; NONHUMAN; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; UPREGULATION; WOUND HEALING;

ANIMALS; CORNEA; CORNEAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION; HUMANS; LYMPHANGIOGENESIS; MATRIX METALLOPROTEINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOUND HEALING;

EID: 77951206611     PISSN: 13509462     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.preteyeres.2010.01.002     Document Type: Review

References (415)

1. Abbas A., Khan B., Feroze A.H., Hyman G.F. Thalidomide prevents donor corneal graft neovascularization in an alkali burn model of corneal angiogenesis. J. Pak. Med. Assoc. 2002, 52:476-482.
2. Abdiu O., Van Setten G. Antiangiogenic activity in tears: presence of pigment-epithelium-derived factor. New insights and preliminary results. Ophthalmic Res. 2008, 40:16-18.
3. Abedi H., Zachary I. Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells. J. Biol. Chem. 1997, 272:15442-15451.
4. Acuff H.B., Sinnamon M., Fingleton B., Boone B., Levy S.E., Chen X., Pozzi A., Carbone D.P., Schwartz D.R., Moin K., Sloane B.F., Matrisian L.M. Analysis of host- and tumor-derived proteinases using a custom dual species microarray reveals a protective role for stromal matrix metalloproteinase-12 in non-small cell lung cancer. Cancer Res. 2006, 66:7968-7975.
5. Adamis A.P., Meklir B., Joyce N.C. In situ injury-induced release of basic-fibroblast growth factor from corneal epithelial cells. Am. J. Pathol. 1991, 139:961-967.
6. Adams R.H., Wilkinson G.A., Weiss C., Diella F., Gale N.W., Deutsch U., Risau W., Klein R. Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev. 1999, 13:295-306.
7. Ahmad N., Feyes D.K., Nieminen A.L., Agarwal R., Mukhtar H. Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J. Natl. Cancer Inst. 1997, 89:1881-1886.
8. Ahn M.R., Kunimasa K., Ohta T., Kumazawa S., Kamihira M., Kaji K., Uto Y., Hori H., Nagasawa H., Nakayama T. Suppression of tumor-induced angiogenesis by Brazilian propolis: major component artepillin C inhibits in vitro tube formation and endothelial cell proliferation. Cancer Lett. 2007, 252:235-243.
9. Akpek E.K., Dart J.K., Watson S., Christen W., Dursun D., Yoo S., O'Brien T.P., Schein O.D., Gottsch J.D. A randomized trial of topical cyclosporin 0.05% in topical steroid-resistant atopic keratoconjunctivitis. Ophthalmology 2004, 111:476-482.
10. Alam A., Herault J.P., Barron P., Favier B., Fons P., Delesque-Touchard N., Senegas I., Laboudie P., Bonnin J., Cassan C., Savi P., Ruggeri B., Carmeliet P., Bono F., Herbert J.M. Heterodimerization with vascular endothelial growth factor receptor-2 (VEGFR-2) is necessary for VEGFR-3 activity. Biochem. Biophys. Res. Commun. 2004, 324:909-915.
11. Alavi A., Hood J.D., Frausto R., Stupack D.G., Cheresh D.A. Role of Raf in vascular protection from distinct apoptotic stimuli. Science 2003, 301:94-96.
12. Albe E., Escalona E., Rajagopal R., Javier J.A., Chang J.H., Azar D.T. Proteomic identification of activin receptor-like kinase-1 as a differentially expressed protein during hyaloid vascular system regression. FEBS Lett. 2005, 579(25):5481-5486.
13. Albe E., Chang J.H., Azar N.F., Ivanov A.R., Azar D.T. Proteomic analysis of the hyaloid vascular system regression during ocular development. J. Proteome Res. 2008, 7(11):4904-4913.
14. Alitalo K., Tammela T., Petrova T.V. Lymphangiogenesis in development and human disease. Nature 2005, 438:946-953.
15. Amano S., Rohan R., Kuroki M., Tolentino M., Adamis A.P. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest. Ophthalmol. Vis. Sci. 1998, 39:18-22.
16. Ambati B.K., Joussen A.M., Ambati J., Moromizato Y., Guha C., Javaherian K., Gillies S., O'Reilly M.S., Adamis A.P. Angiostatin inhibits and regresses corneal neovascularization. Arch. Ophthalmol. 2002, 120:1063-1068.
17. Ambati B.K., Nozaki M., Singh N., Takeda A., Jani P.D., Suthar T., Albuquerque R.J., Richter E., Sakurai E., Newcomb M.T., Kleinman M.E., Caldwell R.B., Lin Q., Ogura Y., Orecchia A., Samuelson D.A., Agnew D.W., St Leger J., Green W.R., Mahasreshti P.J., Curiel D.T., Kwan D., Marsh H., Ikeda S., Leiper L.J., Collinson J.M., Bogdanovich S., Khurana T.S., Shibuya M., Baldwin M.E., Ferrara N., Gerber H.P., De Falco S., Witta J., Baffi J.Z., Raisler B.J., Ambati J. Corneal avascularity is due to soluble VEGF receptor-1. Nature 2006, 443(7114):993-997.
18. Ambati B.K., Patterson E., Jani P., Jenkins C., Higgins E., Singh N., Suthar T., Vira N., Smith K., Caldwell R. Soluble vascular endothelial growth factor receptor-1 contributes to the corneal antiangiogenic barrier. Br. J. Ophthalmol. 2007, 91:505-508.
19. Annabi B., Thibeault S., Lee Y.T., Bousquet-Gagnon N., Eliopoulos N., Barrette S., Galipeau J., Beliveau R. Matrix metalloproteinase regulation of sphingosine-1-phosphate-induced angiogenic properties of bone marrow stromal cells. Exp. Hematol. 2003, 31:640-649.
20. Arbiser J.L., Klauber N., Rohan R., van Leeuwen R., Huang M.T., Fisher C., Flynn E., Byers H.R. Curcumin is an in vivo inhibitor of angiogenesis. Mol. Med. 1998, 4:376-383.
21. Asellius, G., 1627. Asellii Cremonensis Antomici Ticiensis Qua Sententiae Anatomicae multae, nel perperam receptae illustrantur, De Lacteibus sive lacteis venis Quarto Vasorum Mesaroicum genere novo invente Gasp, Mediolani, Milan.
22. Awwad S.T., Heilman M., Hogan R.N., Parmar D.N., Petroll W.M., McCulley J.P., Cavanagh H.D. Severe reactive ischemic posterior segment inflammation in Acanthamoeba keratitis: a new potentially blinding syndrome. Ophthalmology 2007, 114:313-320.
23. Azar D.T. Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). Trans. Am. Ophthalmol. Soc. 2006, 104:264-302.
24. Azar D.T., Casanova F.H., Mimura T., Jain S., Chang J.H. Effect of MT1-MMP deficiency and overexpression in corneal keratocytes on vascular endothelial cell migration and proliferation. Curr. Eye Res. 2008, 33:954-962.
25. Azar, D., Casanova, F., Mimura, T., Jain, S., Han, K., Chang, J. Corneal epithelial MT1-MMP inhibits vascular endothelial cell proliferation and migration. Cornea, in press.
26. Babic A.M., Chen C.C., Lau L.F. Fisp12/mouse connective tissue growth factor mediates endothelial cell adhesion and migration through integrin alphavbeta3, promotes endothelial cell survival, and induces angiogenesis in vivo. Mol. Cell Biol. 1999, 19:2958-2966.
27. Bahar I., Kaiserman I., McAllum P., Rootman D., Slomovic A. Subconjunctival bevacizumab injection for corneal neovascularization. Cornea 2008, 27:142-147.
28. Bahar I., Kaiserman I., McAllum P., Rootman D., Slomovic A. Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium. Curr. Eye Res. 2008, 33:23-28.
29. Banerji S., Ni J., Wang S.X., Clasper S., Su J., Tammi R., Jones M., Jackson D.G. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J. Cell Biol. 1999, 144:789-801.
30. Barros L.F., Belfort R. The effects of the subconjunctival injection of bevacizumab (avastin) on angiogenesis in the rat cornea. An. Acad. Bras. Cienc. 2007, 79:389-394.
31. Beer H.D., Bittner M., Niklaus G., Munding C., Max N., Goppelt A., Werner S. The fibroblast growth factor binding protein is a novel interaction partner of FGF-7, FGF-10 and FGF-22 and regulates FGF activity: implications for epithelial repair. Oncogene 2005, 24:5269-5277.
32. Bek E.L., McMillen M.A. Endothelins are angiogenic. J. Cardiovasc. Pharmacol. 2000, 36:S135-S139.
33. Benelli U., Lepri A., Del Tacca M., Nardi M. FK-506 delays corneal graft rejection in a model of corneal xenotransplantation. J. Ocul. Pharmacol. Ther. 1996, 12:425-431.
34. Benelli U., Ross J.R., Nardi M., Klintworth G.K. Corneal neovascularization induced by xenografts or chemical cautery. Inhibition by cyclosporin A. Invest. Ophthalmol. Vis. Sci. 1997, 38:274-282.
35. BenEzra D., Griffin B.W., Maftzir G., Sharif N.A., Clark A.F. Topical formulations of novel angiostatic steroids inhibit rabbit corneal neovascularization. Invest. Ophthalmol. Vis. Sci. 1997, 38:1954-1962.
36. Berman M.B. Regulation of corneal fibroblast MMP-1 secretion by cytochalasins. Cornea 1994, 13:51-57.
37. Beyer T.A., Werner S., Dickson C., Grose R. Fibroblast growth factor 22 and its potential role during skin development and repair. Exp. Cell Res. 2003, 287:228-236.
38. Bian F., Zhang M.C., Zhu Y. Inhibitory effect of curcumin on corneal neovascularization in vitro and in vivo. Ophthalmologica 2008, 222:178-186.
39. Bikfalvi A., Klein S., Pintucci G., Rifkin D.B. Biological roles of fibroblast growth factor-2. Endocr. Rev. 1997, 18:26-45.
40. Binetruy-Tournaire R., Demangel C., Malavaud B., Vassy R., Rouyre S., Kraemer M., Plouet J., Derbin C., Perret G., Mazie J.C. Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. Embo J. 2000, 19:1525-1533.
41. Biswas P.S., Banerjee K., Zheng M., Rouse B.T. Counteracting corneal immunoinflammatory lesion with interleukin-1 receptor antagonist protein. J. Leukoc. Biol. 2004, 76:868-875.
42. Biswas P.S., Banerjee K., Kim B., Kinchington P.R., Rouse B.T. Role of inflammatory cytokine-induced cyclooxygenase 2 in the ocular immunopathologic disease herpetic stromal keratitis. J. Virol. 2005, 79:10589-10600.
43. Bjorndahl M.A., Cao R., Burton J.B., Brakenhielm E., Religa P., Galter D., Wu L., Cao Y. Vascular endothelial growth factor-a promotes peritumoral lymphangiogenesis and lymphatic metastasis. Cancer Res. 2005, 65:9261-9268.
44. Bock F., Onderka J., Dietrich T., Bachmann B., Kruse F.E., Paschke M., Zahn G., Cursiefen C. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest. Ophthalmol. Vis. Sci. 2007, 48:2545-2552.
45. Bock F., Konig Y., Kruse F., Baier M., Cursiefen C. Bevacizumab (avastin) eye drops inhibit corneal neovascularization. Graefes Arch. Clin. Exp. Ophthalmol. 2008, 246:281-284.
46. Bock F., Onderka J., Dietrich T., Bachmann B., Pytowski B., Cursiefen C. Blockade of VEGFR3-signalling specifically inhibits lymphangiogenesis in inflammatory corneal neovascularisation. Graefes Arch. Clin. Exp. Ophthalmol. 2008, 246:115-119.
47. Bock F., Onderka J., Rummelt C., Dietrich T., Bachmann B., Kruse F.E., Schlotzer-Schrehardt U.M., Cursiefen C. Safety profile of topical VEGF-neutralization at the cornea. Invest. Ophthalmol. Vis. Sci. 2009.
48. Bourges J.L., Lallemand F., Agla E., Besseghir K., Dumont J.M., BenEzra D., Gurny R., Behar-Cohen F. Evaluation of a topical cyclosporine A prodrug on corneal graft rejection in rats. Mol. Vis. 2006, 12:1461-1466.
49. Breier G. Angiogenesis in embryonic development-a review. Placenta 2000, 21(Suppl. A):S11-S15.
50. Brideau G., Makinen M.J., Elamaa H., Tu H., Nilsson G., Alitalo K., Pihlajaniemi T., Heljasvaara R. Endostatin overexpression inhibits lymphangiogenesis and lymph node metastasis in mice. Cancer Res. 2007, 67:11528-11535.
51. Broocker G., Aaron M., Kim J. Injury to the eye. Trauma 2007, 419-435. McGraw Hill Professional. sixth ed. D.V. Feliciano, K.L. Mattox, E.E. Moore (Eds.).
52. Brooks P.C., Montgomery A.M., Rosenfeld M., Reisfeld R.A., Hu T., Klier G., Cheresh D.A. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994, 79:1157-1164.
53. Burman S., Tejwani S., Vemuganti G.K., Gopinathan U., Sangwan V.S. Ophthalmic applications of preserved human amniotic membrane: a review of current indications. Cell Tissue Bank. 2004, 5:161-175.
54. Burton J.B., Priceman S.J., Sung J.L., Brakenhielm E., An D.S., Pytowski B., Alitalo K., Wu L. Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis. Cancer Res. 2008, 68:7828-7837.
55. 3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression. Oncogene 2000, 19:5091-5097.
56. Cao Y. Opinion: emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis. Nat. Rev. Cancer 2005, 5:735-743.
57. Cao Y., Linden P., Shima D., Browne F., Folkman J. In vivo angiogenic activity and hypoxia induction of heterodimers of placenta growth factor/vascular endothelial growth factor. J. Clin. Invest. 1996, 98:2507-2511.
58. Cao Y., Linden P., Farnebo J., Cao R., Eriksson A., Kumar V., Qi J.H., Claesson-Welsh L., Alitalo K. Vascular endothelial growth factor C induces angiogenesis in vivo. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:14389-14394.
59. Cao W., Tombran-Tink J., Chen W., Mrazek D., Elias R., McGinnis J.F. Pigment epithelium-derived factor protects cultured retinal neurons against hydrogen peroxide-induced cell death. J. Neurosci. Res. 1999, 57:789-800.
60. Cao R., Eriksson A., Kubo H., Alitalo K., Cao Y., Thyberg J. Comparative evaluation of FGF-2-, VEGF-A-, and VEGF-C-induced angiogenesis, lymphangiogenesis, vascular fenestrations, and permeability. Circ. Res. 2004, 94:664-670.
61. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005, 69(Suppl. 3):4-10.
62. Carmichael T. Corneal angiogenesis. Ocular Angiogenesis: Diseases, Mechanisms, and Therapeutics 2006, 50-71. Humana Press. J. Tombran-Tink, C.J. Barnstable (Eds.).
63. Carrasco M.A. Subconjunctival bevacizumab for corneal neovascularization in herpetic stromal keratitis. Cornea 2008, 27:743-745.
64. Chang J.H., Gabison E.E., Kato T., Azar D.T. Corneal neovascularization. Curr. Opin. Ophthalmol. 2001, 12:242-249.
65. Chang L., Kaipainen A., Folkman J. Lymphangiogenesis new mechanisms. Ann. N. Y. Acad. Sci. 2002, 979:111-119.
66. Chang L.K., Garcia-Cardena G., Farnebo F., Fannon M., Chen E.J., Butterfield C., Moses M.A., Mulligan R.C., Folkman J., Kaipainen A. Dose-dependent response of FGF-2 for lymphangiogenesis. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:11658-11663.
67. Chang J.H., Javier J.A., Chang G.Y., Oliveira H.B., Azar D.T. Functional characterization of neostatins, the MMP-derived, enzymatic cleavage products of type XVIII collagen. FEBS Lett. 2005, 579:3601-3606.
68. Chen J.X., Chen Y., DeBusk L., Lin W., Lin P.C. Dual functional roles of Tie-2/angiopoietin in TNF-alpha-mediated angiogenesis. Am. J. Physiol. Heart Circ. Physiol. 2004, 287:H187-H195.
69. Chen W.L., Lin C.T., Lin N.T., Tu I.H., Li J.W., Chow L.P., Liu K.R., Hu F.R. Subconjunctival injection of bevacizumab (avastin) inhibits corneal neovascularization in different rabbit models of corneal angiogenesis. Invest. Ophthalmol. Vis. Sci. 2008.
70. Cheng K.H., Leung S.L., Hoekman H.W., Beekhuis W.H., Mulder P.G., Geerards A.J., Kijlstra A. Incidence of contact-lens-associated microbial keratitis and its related morbidity. Lancet 1999, 354:181-185.
71. Cheng H.C., Yeh S.I., Tsao Y.P., Kuo P.C. Subconjunctival injection of recombinant AAV-angiostatin ameliorates alkali burn induced corneal angiogenesis. Mol. Vis. 2007, 13:2344-2352.
72. Chiang C.C., Chen W.L., Lin J.M., Tsai Y.Y. Effect of bevacizumab on human corneal endothelial cells: a six-month follow-up study. Am. J. Ophthalmol. 2008, 146:688-691.
73. Cho W.G., Albuquerque R.J., Kleinman M.E., Tarallo V., Greco A., Nozaki M., Green M.G., Baffi J.Z., Ambati B.K., De Falco M., Alexander J.S., Brunetti A., De Falco S., Ambati J. Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:7137-7142.
74. Chui J., Di Girolamo N., Coroneo M.T., Wakefield D. The role of substance P in the pathogenesis of pterygia. Invest. Ophthalmol. Vis. Sci. 2007, 48:4482-4489.
75. Chung E.S., Saban D.R., Chauhan S.K., Dana R. Regulation of blood vessel versus lymphatic vessel growth in the cornea. Invest. Ophthalmol. Vis. Sci. 2009, 50:1613-1618.
76. Cohen R.A., Gebhardt B.M., Bazan N.G. A platelet-activating factor antagonist reduces corneal allograft inflammation and neovascularization. Curr. Eye Res. 1994, 13:139-144.
77. Collin H.B. Lymphatic drainage of 131-I-albumin from the vascularized cornea. Invest. Ophthalmol. 1970, 9:146-155.
78. Colorado P.C., Torre A., Kamphaus G., Maeshima Y., Hopfer H., Takahashi K., Volk R., Zamborsky E.D., Herman S., Sarkar P.K., Ericksen M.B., Dhanabal M., Simons M., Post M., Kufe D.W., Weichselbaum R.R., Sukhatme V.P., Kalluri R. Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res. 2000, 60:2520-2526.
79. Cornelius L.A., Nehring L.C., Harding E., Bolanowski M., Welgus H.G., Kobayashi D.K., Pierce R.A., Shapiro S.D. Matrix metalloproteinases generate angiostatin: effects on neovascularization. J. Immunol. 1998, 161:6845-6852.
80. Crabtree B., Holloway D.E., Baker M.D., Acharya K.R., Subramanian V. Biological and structural features of murine angiogenin-4, an angiogenic protein. Biochemistry 2007, 46:2431-2443.
81. Cueni L., Detmar M. Lymphatic vascular system and lymphangiogenesis. Angiogenesis: an Integrative Approach from Science to Medicine 2008, 505-516. Springer. W.D. Figg, J. Folkman (Eds.).
82. Cueni L.N., Detmar M. The lymphatic system in health and disease. Lymphat Res. Biol. 2008, 6:109-122.
83. Cursiefen C. Immune privilege and angiogenic privilege of the cornea. Chem. Immunol. Allergy 2007, 92:50-57.
84. Cursiefen C., Rummelt C., Kuchle M. Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta1 in human corneas with neovascularization. Cornea 2000, 19:526-533.
85. Cursiefen C., Cao J., Chen L., Liu Y., Maruyama K., Jackson D., Kruse F.E., Wiegand S.J., Dana M.R., Streilein J.W. Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest. Ophthalmol. Vis. Sci. 2004, 45:2666-2673.
86. Cursiefen C., Chen L., Saint-Geniez M., Hamrah P., Jin Y., Rashid S., Pytowski B., Persaud K., Wu Y., Streilein J.W., Dana R. Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc. Natl. Acad. Sci. U. S. A. 2006, 103(30):11405-11410.
87. Cursiefen C., Kruse F. New aspects of angiogenesis in the cornea. Essentials Ophthalmol. 2006, 83-99.
88. Dadgostar H., Waheed N. The evolving role of vascular endothelial growth factor inhibitors in the treatment of neovascular age-related macular degeneration. Eye 2008, 22:761-767.
89. Dam T.N., Moller B., Hindkjaer J., Kragballe K. The vitamin D3 analog calcipotriol suppresses the number and antigen-presenting function of Langerhans cells in normal human skin. J. Investig. Dermatol. Symp. Proc. 1996, 1:72-77.
90. Dan L., Shi-long Y., Miao-li L., Yong-ping L., Hong-jie M., Ying Z., Xiang-gui W. Inhibitory effect of oral doxycycline on neovascularization in a rat corneal alkali burn model of angiogenesis. Curr. Eye Res. 2008, 33:653-660.
91. Dana R. Comparison of topical interleukin-1 vs tumor necrosis factor-alpha blockade with corticosteroid therapy on murine corneal inflammation, neovascularization, and transplant survival (an American Ophthalmological Society thesis). Trans. Am. Ophthalmol. Soc. 2007, 105:330-343.
92. Daniel T.O., Stein E., Cerretti D.P., St John P.L., Robert B., Abrahamson D.R. ELK and LERK-2 in developing kidney and microvascular endothelial assembly. Kidney Int. Suppl. 1996, 57:S73-S81.
93. Darland D.C., D'Amore P.A. Cell-cell interactions in vascular development. Curr. Top. Dev. Biol. 2001, 52:107-149.
94. Davanger M., Evensen A. Role of the pericorneal papillary structure in renewal of corneal epithelium. Nature 1971, 229:560-561.
95. Davis S., Gale N.W., Aldrich T.H., Maisonpierre P.C., Lhotak V., Pawson T., Goldfarb M., Yancopoulos G.D. Ligands for EPH-related receptor tyrosine kinases that require membrane attachment or clustering for activity. Science 1994, 266:816-819.
96. Dawson D.W., Volpert O.V., Gillis P., Crawford S.E., Xu H., Benedict W., Bouck N.P. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999, 285:245-248.
97. Dean R.A., Butler G.S., Hamma-Kourbali Y., Delbe J., Brigstock D.R., Courty J., Overall C.M. Identification of candidate angiogenic inhibitors processed by matrix metalloproteinase 2 (MMP-2) in cell-based proteomic screens: disruption of vascular endothelial growth factor (VEGF)/heparin affin regulatory peptide (pleiotrophin) and VEGF/Connective tissue growth factor angiogenic inhibitory complexes by MMP-2 proteolysis. Mol. Cell. Biol. 2007, 27:8454-8465.
98. Dell S., Peters S., Muther P., Kociok N., Joussen A.M. The role of PDGF receptor inhibitors and PI3-kinase signaling in the pathogenesis of corneal neovascularization. Invest. Ophthalmol. Vis. Sci. 2006, 47:1928-1937.
99. Dell'Eva R., Pfeffer U., Indraccolo S., Albini A., Noonan D. Inhibition of tumor angiogenesis by angiostatin: from recombinant protein to gene therapy. Endothelium 2002, 9:3-10.
100. Dhanabal M., Ramchandran R., Waterman M.J., Lu H., Knebelmann B., Segal M., Sukhatme V.P. Endostatin induces endothelial cell apoptosis. J. Biol. Chem. 1999, 274:11721-11726.
101. Di Girolamo N., Coroneo M.T., Wakefield D. Active matrilysin (MMP-7) in human pterygia: potential role in angiogenesis. Invest. Ophthalmol. Vis. Sci. 2001, 42:1963-1968.
102. Dixelius J., Makinen T., Wirzenius M., Karkkainen M.J., Wernstedt C., Alitalo K., Claesson-Welsh L. Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites. J. Biol. Chem. 2003, 278:40973-40979.
103. Doctor P.P., Bhat P.V., Foster C.S. Subconjunctival bevacizumab for corneal neovascularization. Cornea 2008, 27:992-995.
104. Dong Z., Ghabrial M., Katar M., Fridman R., Berk R.S. Membrane-type matrix metalloproteinases in mice intracorneally infected with Pseudomonas aeruginosa. Invest. Ophthalmol. Vis. Sci. 2000, 41:4189-4194.
105. Dong Z., Katar M., Alousi S., Berk R.S. Expression of membrane-type matrix metalloproteinases 4, 5, and 6 in mouse corneas infected with P. aeruginosa. Invest. Ophthalmol. Vis. Sci. 2001, 42:3223-3227.
106. Duenas Z., Torner L., Corbacho A.M., Ochoa A., Gutierrez-Ospina G., Lopez-Barrera F., Barrios F.A., Berger P., Martinez de la Escalera G., Clapp C. Inhibition of rat corneal angiogenesis by 16-kDa prolactin and by endogenous prolactin-like molecules. Invest. Ophthalmol. Vis. Sci. 1999, 40:2498-2505.
107. Duke-Elder S. Corneal Wound Healing 1958, Henry Klimpton, London.
108. Dushku N., John M.K., Schultz G.S., Reid T.W. Pterygia pathogenesis: corneal invasion by matrix metalloproteinase expressing altered limbal epithelial basal cells. Arch. Ophthalmol. 2001, 119:695-706.
109. Elder M.J., Dart J.K., Lightman S. Conjunctival fibrosis in ocular cicatricial pemphigoid - the role of cytokines. Exp. Eye Res. 1997, 65:165-176.
110. Eliceiri B.P. Integrin and growth factor receptor crosstalk. Circ. Res. 2001, 89:1104-1110.
111. Eliceiri B.P., Paul R., Schwartzberg P.L., Hood J.D., Leng J., Cheresh D.A. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol. Cell 1999, 4:915-924.
112. Eliceiri B.P., Puente X.S., Hood J.D., Stupack D.G., Schlaepfer D.D., Huang X.Z., Sheppard D., Cheresh D.A. Src-mediated coupling of focal adhesion kinase to integrin alpha(v)beta5 in vascular endothelial growth factor signaling. J. Cell Biol. 2002, 157:149-160.
113. Erie J.C., Nevitt M.P., Hodge D.O., Ballard D.J. Incidence of ulcerative keratitis in a defined population from 1950 through 1988. Arch. Ophthalmol. 1993, 111:1665-1671.
114. Eriksson A., Cao R., Pawliuk R., Berg S.M., Tsang M., Zhou D., Fleet C., Tritsaris K., Dissing S., Leboulch P., Cao Y. Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers. Cancer Cell 2002, 1:99-108.
115. Eriksson K., Magnusson P., Dixelius J., Claesson-Welsh L., Cross M.J. Angiostatin and endostatin inhibit endothelial cell migration in response to FGF and VEGF without interfering with specific intracellular signal transduction pathways. FEBS Lett. 2003, 536:19-24.
116. Espana E.M., Grueterich M., Romano A.C., Touhami A., Tseng S.C. Idiopathic limbal stem cell deficiency. Ophthalmology 2002, 109:2004-2010.
117. Espana E.M., Ti S.E., Grueterich M., Touhami A., Tseng S.C. Corneal stromal changes following reconstruction by ex vivo expanded limbal epithelial cells in rabbits with total limbal stem cell deficiency. Br. J. Ophthalmol. 2003, 87:1509-1514.
118. Felbor U., Dreier L., Bryant R.A., Ploegh H.L., Olsen B.R., Mothes W. Secreted cathepsin L generates endostatin from collagen XVIII. Embo J. 2000, 19:1187-1194.
119. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am. J. Physiol. Cell Physiol. 2001, 280:C1358-C1366.
120. Ferreras M., Felbor U., Lenhard T., Olsen B.R., Delaisse J. Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett. 2000, 486:247-251.
121. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971, 285:1182-1186.
122. Folkman J. History of angiogenesis. Angiogenesis: an Integrative Approach from Science to Medicine 2008, 1-14. Springer. W.D. Figg, J. Folkman (Eds.).
123. Folkman J., D'Amore P.A. Blood vessel formation: what is its molecular basis?. Cell 1996, 87:1153-1155.
124. Fournier E., Blaikie P., Rosnet O., Margolis B., Birnbaum D., Borg J.P. Role of tyrosine residues and protein interaction domains of SHC adaptor in VEGF receptor 3 signaling. Oncogene 1999, 18:507-514.
125. Framme C., Flucke B., Birngruber R. Comparison of reduced and standard light application in photodynamic therapy of the eye in two rabbit models. Graefes Arch. Clin. Exp. Ophthalmol. 2006, 244:773-781.
126. Friedenwald J.S. Growth pressure and metaplasia of conjunctival and corneal epithelium. Doc. Ophthalmol. 1951, 5-6:184-192.
127. Friedlander M., Brooks P.C., Shaffer R.W., Kincaid C.M., Varner J.A., Cheresh D.A. Definition of two angiogenic pathways by distinct alpha v integrins. Science 1995, 270:1500-1502.
128. Friling R., Yassur Y., Levy R., Kost J., Schwartz B., Mikhailowsky R., Lamprecht S.A. A role of transforming growth factor-beta 1 in the control of corneal neovascularization. In Vivo 1996, 10:59-64.
129. Frucht J., Zauberman H. Topical indomethacin effect on neovascularisation of the cornea and on prostaglandin E2 levels. Br. J. Ophthalmol. 1984, 68:656-659.
130. Fukumoto S., Morifuji M., Katakura Y., Ohishi M., Nakamura S. Endostatin inhibits lymph node metastasis by a down-regulation of the vascular endothelial growth factor C expression in tumor cells. Clin. Exp. Metastasis 2005, 22:31-38.
131. Gabison E., Chang J.H., Hernandez-Quintela E., Javier J., Lu P.C., Ye H., Kure T., Kato T., Azar D.T. Anti-angiogenic role of angiostatin during corneal wound healing. Exp. Eye Res. 2004, 78(3):579-589.
132. Gagliano N., Moscheni C., Torri C., Magnani I., Bertelli A.A., Gioia M. Effect of resveratrol on matrix metalloproteinase-2 (MMP-2) and secreted protein acidic and rich in cysteine (SPARC) on human cultured glioblastoma cells. Biomed. Pharmacother. 2005, 59:359-364.
133. Gale N.W., Yancopoulos G.D. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev. 1999, 13:1055-1066.
134. Gerety S.S., Wang H.U., Chen Z.F., Anderson D.J. Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development. Mol. Cell 1999, 4:403-414.
135. Gerten G. Bevacizumab (avastin) and argon laser to treat neovascularization in corneal transplant surgery. Cornea 2008, 27:1195-1199.
136. Gimbrone M.A., Cotran R.S., Leapman S.B., Folkman J. Tumor growth and neovascularization: an experimental model using the rabbit cornea. J. Natl. Cancer Inst. 1974, 52:413-427.
137. Gingras D., Bousquet-Gagnon N., Langlois S., Lachambre M.P., Annabi B., Beliveau R. Activation of the extracellular signal-regulated protein kinase (ERK) cascade by membrane-type-1 matrix metalloproteinase (MT1-MMP). FEBS Lett. 2001, 507:231-236.
138. Gipson I.K. The epithelial basement membrane zone of the limbus. Eye 1989, 3(Pt 2):132-140.
139. Gipson I., Joyce N., Zieske J. The anatomy and cell biology of the human cornea, limbus, conjunctiva. Smolin and Thoft's the Cornea: Scientific Foundations and Clinical Practice 2005, 1-35. Lippincott Williams and Wilkins. fourth ed. S.C. Foster, D.T. Azar, C.H. Dohlman (Eds.).
140. Gipson I.K., Joyce N.C. Anatomy and cell biology of the cornea, superficial limbus and conjunctiva. Principles and Practice of Ophthalmology 1999, 612-629. WB Saunders, Philadelphia. D.M. Albert, F.A. Jakobiec (Eds.).
141. Goldman J., Rutkowski J.M., Shields J.D., Pasquier M.C., Cui Y., Schmokel H.G., Willey S., Hicklin D.J., Pytowski B., Swartz M.A. Cooperative and redundant roles of VEGFR-2 and VEGFR-3 signaling in adult lymphangiogenesis. Faseb J. 2007, 21:1003-1012.
142. Gordon Y.J., Mann R.K., Mah T.S., Gorin M.B. Fluorescein-potentiated argon laser therapy improves symptoms and appearance of corneal neovascularization. Cornea 2002, 21:770-773.
143. Goto T., Ishikawa H., Matsumoto K., Nishimura D., Kusaba M., Taura N., Shibata H., Miyaaki H., Ichikawa T., Hamasaki K., Nakao K., Maeshima Y., Eguchi K. Tum-1, a tumstatin fragment, gene delivery into hepatocellular carcinoma suppresses tumor growth through inhibiting angiogenesis. Int. J. Oncol. 2008, 33:33-40.
144. Graells J., Vinyals A., Figueras A., Llorens A., Moreno A., Marcoval J., Gonzalez F.J., Fabra A. Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling. J. Invest. Dermatol. 2004, 123:1151-1161.
145. Grierson I., Heathcote L., Hiscott P., Hogg P., Briggs M., Hagan S. Hepatocyte growth factor/scatter factor in the eye. Prog. Retin. Eye Res. 2000, 19:779-802.
146. Grisanti S., Tatar O. The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration. Prog. Retin. Eye Res. 2008, 27:372-390.
147. Griscelli F., Li H., Bennaceur-Griscelli A., Soria J., Opolon P., Soria C., Perricaudet M., Yeh P., Lu H. Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:6367-6372.
148. Grueterich M., Espana E.M., Tseng S.C. Ex vivo expansion of limbal epithelial stem cells: amniotic membrane serving as a stem cell niche. Surv. Ophthalmol. 2003, 48:631-646.
149. Gu W.Z., Tahir S.K., Wang Y.C., Zhang H.C., Cherian S.P., O'Connor S., Leal J.A., Rosenberg S.H., Ng S.C. Effect of novel CAAX peptidomimetic farnesyltransferase inhibitor on angiogenesis in vitro and in vivo. Eur. J. Cancer 1999, 35:1394-1401.
150. Guo D., Jia Q., Song H.Y., Warren R.S., Donner D.B. Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation. J. Biol. Chem. 1995, 270:6729-6733.
151. Ha C.H., Jhun B.S., Kao H.Y., Jin Z.G. VEGF stimulates HDAC7 phosphorylation and cytoplasmic accumulation modulating matrix metalloproteinase expression and angiogenesis. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1782-1788.
152. Hajitou A., Grignet C., Devy L., Berndt S., Blacher S., Deroanne C.F., Bajou K., Fong T., Chiang Y., Foidart J.M., Noel A. The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells. Faseb J. 2002, 16:1802-1804.
153. Hamada K., Oike Y., Takakura N., Ito Y., Jussila L., Dumont D.J., Alitalo K., Suda T. VEGF-C signaling pathways through VEGFR-2 and VEGFR-3 in vasculoangiogenesis and hematopoiesis. Blood 2000, 96:3793-3800.
154. Han J., Lim C.J., Watanabe N., Soriani A., Ratnikov B., Calderwood D.A., Puzon-McLaughlin W., Lafuente E.M., Boussiotis V.A., Shattil S.J., Ginsberg M.H. Reconstructing and deconstructing agonist-induced activation of integrin alphaIIbbeta3. Curr. Biol. 2006, 16:1796-1806.
155. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86(3):353-364.
156. Hayashi K., Hooper L.C., Detrick B., Hooks J.J. HSV immune complex (HSV-IgG: IC) and HSV-DNA elicit the production of angiogenic factor VEGF and MMP-9. Arch. Virol. 2009, 154:219-226.
157. He Y., Kozaki K., Karpanen T., Koshikawa K., Yla-Herttuala S., Takahashi T., Alitalo K. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J. Natl. Cancer Inst. 2002, 94:819-825.
158. He Y., Karpanen T., Alitalo K. Role of lymphangiogenic factors in tumor metastasis. Biochim. Biophys. Acta 2004, 1654:3-12.
159. He Y., Rajantie I., Ilmonen M., Makinen T., Karkkainen M.J., Haiko P., Salven P., Alitalo K. Preexisting lymphatic endothelium but not endothelial progenitor cells are essential for tumor lymphangiogenesis and lymphatic metastasis. Cancer Res. 2004, 64:3737-3740.
160. Hernandez G.L., Volpert O.V., Iniguez M.A., Lorenzo E., Martinez-Martinez S., Grau R., Fresno M., Redondo J.M. Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2. J. Exp. Med. 2001, 193:607-620.
161. Hirata S., Matsubara T., Saura R., Tateishi H., Hirohata K. Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. Arthritis Rheum. 1989, 32:1065-1073.
162. Holick M.F., Uskokovic M., Henley J.W., MacLaughlin J., Holick S.A., Potts J.T. The photoproduction of 1 alpha,25-dihydroxyvitamin D3 in skin: an approach to the therapy of vitamin-D-resistant syndromes. N. Engl. J. Med. 1980, 303:349-354.
163. Hosseini H., Nejabat M., Mehryar M., Yazdchi T., Sedaghat A., Noori F. Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis. Clin. Exp. Ophthalmol. 2007, 35:745-748.
164. Houghton A.M., Grisolano J.L., Baumann M.L., Kobayashi D.K., Hautamaki R.D., Nehring L.C., Cornelius L.A., Shapiro S.D. Macrophage elastase (matrix metalloproteinase-12) suppresses growth of lung metastases. Cancer Res. 2006, 66:6149-6155.
165. Hu L., Roth J.M., Brooks P., Luty J., Karpatkin S. Thrombin up-regulates cathepsin D which enhances angiogenesis, growth, and metastasis. Cancer Res. 2008, 68:4666-4673.
166. Huang A.J., Li D.Q., Li C.H., Shang T.Y., Hernandez E. Modulation of corneal vascularization. Ocul. Surf. 2005, 3:S190-S193.
167. Huang A.J., Tseng S.C. Corneal epithelial wound healing in the absence of limbal epithelium. Invest. Ophthalmol. Vis. Sci. 1991, 32:96-105.
168. Hunter J. Lectures on the principles of surgery. The Works of John Hunter 1787, J. Palmer (Ed.).
169. Huynh-Do U., Vindis C., Liu H., Cerretti D.P., McGrew J.T., Enriquez M., Chen J., Daniel T.O. Ephrin-B1 transduces signals to activate integrin-mediated migration, attachment and angiogenesis. J. Cell Sci. 2002, 115:3073-3081.
170. Ide A., Baker N., Warren S. Vascularization of the brown Pearce rabbit epithelioma transplant as seen in the transparent ear chamber. Am. J. Roentgenol. 1939, 42:891-899.
171. Iozzo R.V. The family of the small leucine-rich proteoglycans: key regulators of matrix assembly and cellular growth. Crit. Rev. Biochem. Mol. Biol. 1997, 32:141-174.
172. Itoh T., Tanioka M., Yoshida H., Yoshioka T., Nishimoto H., Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. 1998, 58:1048-1051.
173. Jakobiec F.A., Ozanics V. General topographic anatomy of the eye. Ocular Anatomy, Embryology, Teratology 1982, Philadelphia, Harper & Row. F.A. Jakobiec (Ed.).
174. Jeffers M., Shimkets R., Prayaga S., Boldog F., Yang M., Burgess C., Fernandes E., Rittman B., Shimkets J., LaRochelle W.J., Lichenstein H.S. Identification of a novel human fibroblast growth factor and characterization of its role in oncogenesis. Cancer Res. 2001, 61:3131-3138.
175. Jeon B.H., Jang C., Han J., Kataru R.P., Piao L., Jung K., Cha H.J., Schwendener R.A., Jang K.Y., Kim K.S., Alitalo K., Koh G.Y. Profound but dysfunctional lymphangiogenesis via vascular endothelial growth factor ligands from CD11b+ macrophages in advanced ovarian cancer. Cancer Res. 2008, 68:1100-1109.
176. Jia W.D., Xu G.L., Sun H.C., Wang L., Xu R.N., Xue Q. Effect of octreotide on angiogenesis induced by hepatocellular carcinoma in vivo. Hepatobiliary Pancreat. Dis. Int. 2003, 2:404-409.
177. Jin J., Guan M., Sima J., Gao G., Zhang M., Liu Z., Fant J., Ma J.X. Decreased pigment epithelium-derived factor and increased vascular endothelial growth factor levels in pterygia. Cornea 2003, 22:473-477.
178. Jo N., Mailhos C., Ju M., Cheung E., Bradley J., Nishijima K., Robinson G.S., Adamis A.P., Shima D.T. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am. J. Pathol. 2006, 168:2036-2053.
179. Joussen A.M., Kruse F.E., Volcker H.E., Kirchhof B. Topical application of methotrexate for inhibition of corneal angiogenesis. Graefes Arch. Clin. Exp. Ophthalmol. 1999, 237:920-927.
180. Jung H.J., Shim J.S., Suh Y.G., Kim Y.M., Ono M., Kwon H.J. Potent inhibition of in vivo angiogenesis and tumor growth by a novel cyclooxygenase-2 inhibitor, enoic acanthoic acid. Cancer Sci. 2007, 98:1943-1948.
181. Kadar T., Dachir S., Cohen L., Sahar R., Fishbine E., Cohen M., Turetz J., Gutman H., Buch H., Brandeis R., Horwitz V., Solomon A., Amir A. Ocular injuries following sulfur mustard exposure-pathological mechanism and potential therapy. Toxicology 2008.
182. Kaipainen A., Korhonen J., Mustonen T., van Hinsbergh V.W., Fang G.H., Dumont D., Breitman M., Alitalo K. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:3566-3570.
183. Kajanne R., Miettinen P., Mehlem A., Leivonen S.K., Birrer M., Foschi M., Kahari V.M., Leppa S. EGF-R regulates MMP function in fibroblasts through MAPK and AP-1 pathways. J. Cell Physiol. 2007, 212:489-497.
184. Karakousis P.C., John S.K., Behling K.C., Surace E.M., Smith J.E., Hendrickson A., Tang W.X., Bennett J., Milam A.H. Localization of pigment epithelium derived factor (PEDF) in developing and adult human ocular tissues. Mol. Vis. 2001, 7:154-163.
185. Karkkainen M.J., Ferrell R.E., Lawrence E.C., Kimak M.A., Levinson K.L., McTigue M.A., Alitalo K., Finegold D.N. Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat. Genet. 2000, 25:153-159.
186. Karkkainen M.J., Haiko P., Sainio K., Partanen J., Taipale J., Petrova T.V., Jeltsch M., Jackson D.G., Talikka M., Rauvala H., Betsholtz C., Alitalo K. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat. Immunol. 2004, 5:74-80.
187. Karpanen T., Alitalo K. Molecular biology and pathology of lymphangiogenesis. Annu. Rev. Pathol. 2008, 3:367-397.
188. Karpanen T., Alitalo K. VEGF-D: a modifier of embryonic lymphangiogenesis. Blood 2008, 112:1547-1548.
189. Kato T., Kure T., Chang J.H., Gabison E.E., Itoh T., Itohara S., Azar D.T. Diminished corneal angiogenesis in gelatinase A-deficient mice. FEBS Lett. 2001, 508:187-190.
190. Kawashima M., Kawakita T., Satake Y., Higa K., Shimazaki J. Phenotypic study after cultivated limbal epithelial transplantation for limbal stem cell deficiency. Arch. Ophthalmol. 2007, 125:1337-1344.
191. Kaye S., Choudhary A. Herpes simplex keratitis. Prog. Retin. Eye Res. 2006, 25:355-380.
192. Keay L., Radford C., Dart J.K., Edwards K., Stapleton F. Perspective on 15 years of research: reduced risk of microbial keratitis with frequent-replacement contact lenses. Eye Contact Lens 2007, 33:167-168.
193. Kenyon K.R., Fogle J.A., Stone D.L., Stark W.J. Regeneration of corneal epithelial basement membrane following thermal cauterization. Invest. Ophthalmol. Vis. Sci. 1977, 16:292-301.
194. Kenyon K.R., Tseng S.C. Limbal autograft transplantation for ocular surface disorders. Ophthalmology 1989, 96:709-722. (discussion 722-703).
195. Keshavarz M., Mostafaie A., Mansouri K., Shakiba Y., Motlagh H.R. Inhibition of corneal neovascularization with propolis extract. Arch. Med. Res. 2009, 40:59-61.
196. Kheirkhah A., Johnson D.A., Paranjpe D.R., Raju V.K., Casas V., Tseng S.C. Temporary sutureless amniotic membrane patch for acute alkaline burns. Arch. Ophthalmol. 2008, 126:1059-1066.
197. Kim Y.M., Hwang S., Kim Y.M., Pyun B.J., Kim T.Y., Lee S.T., Gho Y.S., Kwon Y.G. Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J. Biol. Chem. 2002, 277:27872-27879.
198. Kim B., Lee S., Suvas S., Rouse B.T. Application of plasmid DNA encoding IL-18 diminishes development of herpetic stromal keratitis by antiangiogenic effects. J. Immunol. 2005, 175:509-516.
199. Kim S.W., Ha B.J., Kim E.K., Tchah H., Kim T.I. The effect of topical bevacizumab on corneal neovascularization. Ophthalmology 2008, 115:e33-e38.
200. Kim J.C., Tseng S.C. Transplantation of preserved human amniotic membrane for surface reconstruction in severely damaged rabbit corneas. Cornea 1995, 14:473-484.
201. Kisker O., Onizuka S., Banyard J., Komiyama T., Becker C.M., Achilles E.G., Barnes C.M., O'Reilly M.S., Folkman J., Pirie-Shepherd S.R. Generation of multiple angiogenesis inhibitors by human pancreatic cancer. Cancer Res. 2001, 61:7298-7304.
202. Klein R. Eph/ephrin signaling in morphogenesis, neural development and plasticity. Curr. Opin. Cell Biol. 2004, 16:580-589.
203. Kojima T., Chang J.H., Azar D.T. Proangiogenic role of ephrinB1/EphB1 in basic fibroblast growth factor-induced corneal angiogenesis. Am. J. Pathol. 2007, 170(2):764-773.
204. Kojima T., Chung T.Y., Chang J.H., Sayegh R., Casanova F.H., Azar D.T. Comparison of EphA receptor tyrosine kinases and ephrinA ligand expression to EphB-ephrinB in vascularized corneas. Cornea 2007, 26:569-578.
205. Kojima T., Azar D.T., Chang J.H. Neostatin-7 regulates bFGF-induced corneal lymphangiogenesis. FEBS Lett. 2008, 582(17):2515-2520.
206. Komarova Y., Malik A.B. FGF signaling preserves the integrity of endothelial adherens junctions. Dev. Cell 2008, 15:335-336.
207. Kommineni V.K., Nagineni C.N., William A., Detrick B., Hooks J.J. IFN-gamma acts as anti-angiogenic cytokine in the human cornea by regulating the expression of VEGF-A and sVEGF-R1. Biochem. Biophys. Res. Commun. 2008, 374:479-484.
208. Kruse F.E., Joussen A.M., Rohrschneider K., Becker M.D., Volcker H.E. Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefes Arch. Clin. Exp. Ophthalmol. 1998, 236:461-466.
209. + influx. Acta Physiol. Scand. 2005, 183:161-169.
210. Kullander K., Klein R. Mechanisms and functions of Eph and ephrin signalling. Nat. Rev. Mol. Cell Biol. 2002, 3:475-486.
211. Kure T., Chang J.H., Kato T., Hernandez-Quintela E., Ye H., Lu P.C., Matrisian L.M., Gatinel D., Shapiro S., Gosheh F., Azar D.T. Corneal neovascularization after excimer keratectomy wounds in matrilysin-deficient mice. Invest. Ophthalmol. Vis. Sci. 2003, 44:137-144.
212. Kvanta A., Sarman S., Fagerholm P., Seregard S., Steen B. Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization. Exp. Eye Res. 2000, 70:419-428.
213. Kwitko S., Marinho D., Barcaro S., Bocaccio F., Rymer S., Fernandes S., Neumann J. Allograft conjunctival transplantation for bilateral ocular surface disorders. Ophthalmology 1995, 102:1020-1025.
214. Kwon Y.S., Hong H.S., Kim J.C., Shin J.S., Son Y. Inhibitory effect of rapamycin on corneal neovascularization in vitro and in vivo. Invest. Ophthalmol. Vis. Sci. 2005, 46:454-460.
215. Kwon Y.S., Kim J.C. Inhibition of corneal neovascularization by rapamycin. Exp. Mol. Med. 2006, 38:173-179.
216. Lahdenranta J., Hagendoorn J., Padera T.P., Hoshida T., Nelson G., Kashiwagi S., Jain R.K., Fukumura D. Endothelial nitric oxide synthase mediates lymphangiogenesis and lymphatic metastasis. Cancer Res. 2009, 69:2801-2808.
217. Lai L.J., Xiao X., Wu J.H. Inhibition of corneal neovascularization with endostatin delivered by adeno-associated viral (AAV) vector in a mouse corneal injury model. J. Biomed. Sci. 2007, 14:313-322.
218. Lamoreaux W.J., Fitzgerald M.E., Reiner A., Hasty K.A., Charles S.T. Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. Microvasc. Res. 1998, 55:29-42.
219. Lamouille S., Mallet C., Feige J.J., Bailly S. Activin receptor-like kinase 1 is implicated in the maturation phase of angiogenesis. Blood 2002, 100:4495-4501.
220. Langer R., Folkman J. Polymers for the sustained release of proteins and other macromolecules. Nature 1976, 263:797-800.
221. Lee P., Wang C.C., Adamis A.P. Ocular neovascularization: an epidemiologic review. Surv. Ophthalmol. 1998, 43:245-269.
222. Lee S., Jilani S.M., Nikolova G.V., Carpizo D., Iruela-Arispe M.L. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J. Cell Biol. 2005, 169:681-691.
223. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246:1306-1309.
224. Li X., Eriksson U. Novel VEGF family members: VEGF-B, VEGF-C and VEGF-D. Int. J. Biochem. Cell Biol. 2001, 33:421-426.
225. Li D.Q., Shang T.Y., Kim H.S., Solomon A., Lokeshwar B.L., Pflugfelder S.C. Regulated expression of collagenases MMP-1, -8, and -13 and stromelysins MMP-3, -10, and -11 by human corneal epithelial cells. Invest. Ophthalmol. Vis. Sci. 2003, 44:2928-2936.
226. Lijnen H.R., Ugwu F., Bini A., Collen D. Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3). Biochemistry 1998, 37:4699-4702.
227. Lin H.C., Chang J.H., Jain S., Gabison E.E., Kure T., Kato T., Fukai N., Azar D.T. Matrilysin cleavage of corneal collagen type XVIII NC1 domain and generation of a 28-kDa fragment. Invest. Ophthalmol. Vis. Sci. 2001, 42:2517-2524.
228. Lohela M., Saaristo A., Veikkola T., Alitalo K. Lymphangiogenic growth factors, receptors and therapies. Thromb. Haemost. 2003, 90:167-184.
229. Lohela M., Bry M., Tammela T., Alitalo K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr. Opin. Cell Biol. 2009, 21:154-165.
230. London N.R., Whitehead K.J., Li D.Y. Endogenous endothelial cell signaling systems maintain vascular stability. Angiogenesis 2009.
231. Lu P.C., Ye H., Maeda M., Azar D.T. Immunolocalization and gene expression of matrilysin during corneal wound healing. Invest. Ophthalmol. Vis. Sci. 1999, 40:20-27.
232. Luengo Gimeno F., Lavigne V., Gatto S., Croxatto J.O., Correa L., Gallo J.E. Advances in corneal stem-cell transplantation in rabbits with severe ocular alkali burns. J. Cataract Refract. Surg. 2007, 33:1958-1965.
233. Ma X., Ottino P., Bazan H.E., Bazan N.G. Platelet-activating factor (PAF) induces corneal neovascularization and upregulates VEGF expression in endothelial cells. Invest. Ophthalmol. Vis. Sci. 2004, 45:2915-2921.
234. Ma D.H., Chen J.K., Zhang F., Lin K.Y., Yao J.Y., Yu J.S. Regulation of corneal angiogenesis in limbal stem cell deficiency. Prog. Retin. Eye Res. 2006, 25:563-590.
235. Mackenzie S.E., Tucker W.R., Poole T.R. Bevacizumab (avastin) for corneal neovascularization - corneal light shield soaked application. Cornea 2009, 28:246-247.
236. Maekawa H., Oike Y., Kanda S., Ito Y., Yamada Y., Kurihara H., Nagai R., Suda T. Ephrin-B2 induces migration of endothelial cells through the phosphatidylinositol-3 kinase pathway and promotes angiogenesis in adult vasculature. Arterioscler. Thromb. Vasc. Biol. 2003, 23:2008-2014.
237. Maeshima Y., Colorado P.C., Kalluri R. Two RGD-independent alpha vbeta 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. J. Biol. Chem. 2000, 275:23745-23750.
238. Maeshima Y., Manfredi M., Reimer C., Holthaus K.A., Hopfer H., Chandamuri B.R., Kharbanda S., Kalluri R. Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin. J. Biol. Chem. 2001, 276:15240-15248.
239. Maeshima Y., Yerramalla U.L., Dhanabal M., Holthaus K.A., Barbashov S., Kharbanda S., Reimer C., Manfredi M., Dickerson W.M., Kalluri R. Extracellular matrix-derived peptide binds to alpha(v)beta(3) integrin and inhibits angiogenesis. J. Biol. Chem. 2001, 276:31959-31968.
240. Maeshima Y., Sudhakar A., Lively J.C., Ueki K., Kharbanda S., Kahn C.R., Sonenberg N., Hynes R.O., Kalluri R. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 2002, 295:140-143.
241. Magnon C., Galaup A., Mullan B., Rouffiac V., Bouquet C., Bidart J.M., Griscelli F., Opolon P., Perricaudet M. Canstatin acts on endothelial and tumor cells via mitochondrial damage initiated through interaction with alphavbeta3 and alphavbeta5 integrins. Cancer Res. 2005, 65:4353-4361.
242. Magnon C., Opolon P., Ricard M., Connault E., Ardouin P., Galaup A., Metivier D., Bidart J.M., Germain S., Perricaudet M., Schlumberger M. Radiation and inhibition of angiogenesis by canstatin synergize to induce HIF-1alpha-mediated tumor apoptotic switch. J. Clin. Invest. 2007, 117:1844-1855.
243. Maguen E., Zorapapel N.C., Zieske J.D., Ninomiya Y., Sado Y., Kenney M.C., Ljubimov A.V. Extracellular matrix and matrix metalloproteinase changes in human corneas after complicated laser-assisted in situ keratomileusis (LASIK). Cornea 2002, 21:95-100.
244. Mahajan V.B., Wei C., McDonnell P.J. Microarray analysis of corneal fibroblast gene expression after interleukin-1 treatment. Invest. Ophthalmol. Vis. Sci. 2002, 43:2143-2151.
245. Makinen T., Jussila L., Veikkola T., Karpanen T., Kettunen M.I., Pulkkanen K.J., Kauppinen R., Jackson D.G., Kubo H., Nishikawa S., Yla-Herttuala S., Alitalo K. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat. Med. 2001, 7:199-205.
246. Martin A.R., Villegas I., La Casa C., de la Lastra C.A. Resveratrol, a polyphenol found in grapes, suppresses oxidative damage and stimulates apoptosis during early colonic inflammation in rats. Biochem. Pharmacol. 2004, 67:1399-1410.
247. Maruyama K., Ii M., Cursiefen C., Jackson D.G., Keino H., Tomita M., Van Rooijen N., Takenaka H., D'Amore P.A., Stein-Streilein J., Losordo D.W., Streilein J.W. Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. J. Clin. Invest. 2005, 115:2363-2372.
248. Masferrer J.L., Leahy K.M., Koki A.T., Zweifel B.S., Settle S.L., Woerner B.M., Edwards D.A., Flickinger A.G., Moore R.J., Seibert K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 2000, 60:1306-1311.
249. Massague J. TGF-beta signal transduction. Annu. Rev. Biochem. 1998, 67:753-791.
250. Mastyugin V., Mosaed S., Bonazzi A., Dunn M.W., Schwartzman M.L. Corneal epithelial VEGF and cytochrome P450 4B1 expression in a rabbit model of closed eye contact lens wear. Curr. Eye Res. 2001, 23:1-10.
251. Masuda Y., Shimizu A., Mori T., Ishiwata T., Kitamura H., Ohashi R., Ishizaki M., Asano G., Sugisaki Y., Yamanaka N. Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis. Am. J. Pathol. 2001, 159:599-608.
252. Matsui J., Funahashi Y., Uenaka T., Watanabe T., Tsuruoka A., Asada M. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin. Cancer Res. 2008, 14:5459-5465.
253. Matsumura K., Hirashima M., Ogawa M., Kubo H., Hisatsune H., Kondo N., Nishikawa S., Chiba T., Nishikawa S. Modulation of VEGFR-2-mediated endothelial-cell activity by VEGF-C/VEGFR-3. Blood 2003, 101:1367-1374.
254. McNatt L.G., Weimer L., Yanni J., Clark A.F. Angiostatic activity of steroids in the chick embryo CAM and rabbit cornea models of neovascularization. J. Ocul. Pharmacol. Ther. 1999, 15:413-423.
255. Meyer C., Notari L., Becerra S.P. Mapping the type I collagen-binding site on pigment epithelium-derived factor. Implications for its antiangiogenic activity. J. Biol. Chem. 2002, 277:45400-45407.
256. Mills R.A., Jones D.B., Winkler C.R., Wallace G.W., Wilhelmus K.R. Topical FK-506 prevents experimental corneal allograft rejection. Cornea 1995, 14:157-160.
257. Mimura T., Han K.Y., Onguchi T., Chang J.H., Kim T.I., Kojima T., Zhou Z., Azar D.T. MT1-MMP-mediated cleavage of decorin in corneal angiogenesis. J Vasc Res. 2009, 46:541-550.
258. Mohammadi M., Froum S., Hamby J.M., Schroeder M.C., Panek R.L., Lu G.H., Eliseenkova A.V., Green D., Schlessinger J., Hubbard S.R. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. Embo J. 1998, 17:5896-5904.
259. Montezuma S.R., Vavvas D., Miller J.W. Review of the ocular angiogenesis animal models. Semin. Ophthalmol. 2009, 24:52-61.
260. Morimoto T., Aoyagi M., Tamaki M., Yoshino Y., Hori H., Duan L., Yano T., Shibata M., Ohno K., Hirakawa K., Yamaguchi N. Increased levels of tissue endostatin in human malignant gliomas. Clin. Cancer Res. 2002, 8:2933-2938.
261. Morisada T., Oike Y., Yamada Y., Urano T., Akao M., Kubota Y., Maekawa H., Kimura Y., Ohmura M., Miyamoto T., Nozawa S., Koh G.Y., Alitalo K., Suda T. Angiopoietin-1 promotes LYVE-1-positive lymphatic vessel formation. Blood 2005, 105:4649-4656.
262. Moser T.L., Stack M.S., Asplin I., Enghild J.J., Hojrup P., Everitt L., Hubchak S., Schnaper H.W., Pizzo S.V. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:2811-2816.
263. Muether P.S., Dell S., Kociok N., Zahn G., Stragies R., Vossmeyer D., Joussen A.M. The role of integrin alpha5beta1 in the regulation of corneal neovascularization. Exp. Eye Res. 2007, 85:356-365.
264. Munaut C., Noel A., Hougrand O., Foidart J.M., Boniver J., Deprez M. Vascular endothelial growth factor expression correlates with matrix metalloproteinases MT1-MMP, MMP-2 and MMP-9 in human glioblastomas. Int. J. Cancer 2003, 106:848-855.
265. Mundel T.M., Kalluri R. Type IV collagen-derived angiogenesis inhibitors. Microvasc. Res. 2007, 74:85-89.
266. Murakami M., Simons M. Fibroblast growth factor regulation of neovascularization. Curr. Opin. Hematol. 2008, 15:215-220.
267. Nagashima K., Endo A., Ogita H., Kawana A., Yamagishi A., Kitabatake A., Matsuda M., Mochizuki N. Adaptor protein Crk is required for ephrin-B1-induced membrane ruffling and focal complex assembly of human aortic endothelial cells. Mol. Biol. Cell 2002, 13:4231-4242.
268. Nakao S., Hata Y., Miura M., Noda K., Kimura Y.N., Kawahara S., Kita T., Hisatomi T., Nakazawa T., Jin Y., Dana M.R., Kuwano M., Ono M., Ishibashi T., Hafezi-Moghadam A. Dexamethasone inhibits interleukin-1beta-induced corneal neovascularization: role of nuclear factor-kappaB-activated stromal cells in inflammatory angiogenesis. Am. J. Pathol. 2007, 171:1058-1065.
269. Narasaki R., Kuribayashi H., Shimizu K., Imamura D., Sato T., Hasumi K. Bacillolysin MA, a novel bacterial metalloproteinase that produces angiostatin-like fragments from plasminogen and activates protease zymogens in the coagulation and fibrinolysis systems. J. Biol. Chem. 2005, 280:14278-14287.
270. Nespoli A., Vercillo R., di Nola L., Diani L., Giannattasio M., Plevani P., Muzi-Falconi M. Alk1 and Alk2 are two new cell cycle-regulated haspin-like proteins in budding yeast. Cell Cycle 2006, 5:1464-1471.
271. Ng I.O., Poon R.T., Lee J.M., Fan S.T., Ng M., Tso W.K. Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma. Am. J. Clin. Pathol. 2001, 116:838-845.
272. Ng Y.S., Rohan R., Sunday M.E., Demello D.E., D'Amore P.A. Differential expression of VEGF isoforms in mouse during development and in the adult. Dev. Dyn. 2001, 220:112-121.
273. Nomura S., Yoshitomi H., Takano S., Shida T., Kobayashi S., Ohtsuka M., Kimura F., Shimizu H., Yoshidome H., Kato A., Miyazaki M. FGF10/FGFR2 signal induces cell migration and invasion in pancreatic cancer. Br. J. Cancer 2008, 99:305-313.
274. Norrby K. In vivo models of angiogenesis. J. Cell Mol. Med. 2006, 10:588-612.
275. Nyberg P., Xie L., Sugimoto H., Colorado P., Sund M., Holthaus K., Sudhakar A., Salo T., Kalluri R. Characterization of the anti-angiogenic properties of arresten, an alpha1beta1 integrin-dependent collagen-derived tumor suppressor. Exp. Cell Res. 2008, 314:3292-3305.
276. O'Brien T.P., Li Q.J., Sauerburger F., Reviglio V.E., Rana T., Ashraf M.F. The role of matrix metalloproteinases in ulcerative keratolysis associated with perioperative diclofenac use. Ophthalmology 2001, 108:656-659.
277. O'Leary D.D., Wilkinson D.G. Eph receptors and ephrins in neural development. Curr. Opin. Neurobiol. 1999, 9:65-73.
278. O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M., Lane W.S., Cao Y., Sage E.H., Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994, 79:315-328.
279. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead J.R., Olsen B.R., Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88:277-285.
280. Okazaki T., Ni A., Ayeni O.A., Baluk P., Yao L.C., Vossmeyer D., Zischinsky G., Zahn G., Knolle J., Christner C., McDonald D.M. {alpha}5{beta}1 integrin blockade inhibits lymphangiogenesis in airway inflammation. Am. J. Pathol. 2009.
281. Olofsson B., Jeltsch M., Eriksson U., Alitalo K. Current biology of VEGF-B and VEGF-C. Curr. Opin. Biotechnol. 1999, 10:528-535.
282. Onguchi T., Han K.Y., Chang J.H., Azar D.T. Membrane type-1 matrix metalloproteinase potentiates basic fibroblast growth factor-induced corneal neovascularization. Am. J. Pathol. 2009, 174(4):1564-1571.
283. Ono K., Yokoo S., Mimura T., Usui T., Miyata K., Araie M., Yamagami S., Amano S. Autologous transplantation of conjunctival epithelial cells cultured on amniotic membrane in a rabbit model. Mol. Vis. 2007, 13:1138-1143.
284. Otasevic L., Gong N., Ritter T., Mergler S., Pleyer U. Effects of spironolactone on corneal allograft survival in the rat. Ophthalmic Res. 2007, 39:325-329.
285. Page-McCaw A. Remodeling the model organism: matrix metalloproteinase functions in invertebrates. Semin. Cell Dev. Biol. 2008, 19:14-23.
286. Page-McCaw A., Ewald A.J., Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat. Rev. Mol. Cell Biol. 2007, 8:221-233.
287. Pajusola K., Aprelikova O., Armstrong E., Morris S., Alitalo K. Two human FLT4 receptor tyrosine kinase isoforms with distinct carboxy terminal tails are produced by alternative processing of primary transcripts. Oncogene 1993, 8:2931-2937.
288. Pakneshan P., Birsner A.E., Adini I., Becker C.M., D'Amato R.J. Differential suppression of vascular permeability and corneal angiogenesis by nonsteroidal anti-inflammatory drugs. Invest. Ophthalmol. Vis. Sci. 2008, 49:3909-3913.
289. Pal S., Datta K., Mukhopadhyay D. Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res. 2001, 61:6952-6957.
290. Panigrahy D., Kaipainen A., Huang S., Butterfield C.E., Barnes C.M., Fannon M., Laforme A.M., Chaponis D.M., Folkman J., Kieran M.W. PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:985-990.
291. Park H.Y., Kwon H.M., Lim H.J., Hong B.K., Lee J.Y., Park B.E., Jang Y., Cho S.Y., Kim H.S. Potential role of leptin in angiogenesis: leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro. Exp. Mol. Med. 2001, 33:95-102.
292. Pasco S., Brassart B., Ramont L., Maquart F.X., Monboisse J.C. Control of melanoma cell invasion by type IV collagen. Cancer Detect. Prev. 2005, 29:260-266.
293. Patel S.P., Dana R. Corneal lymphangiogenesis: implications in immunity. Semin. Ophthalmol. 2009, 24:135-138.
294. Patterson B.C., Sang Q.A. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J. Biol. Chem. 1997, 272:28823-28825.
295. Penn J.S., Madan A., Caldwell R.B., Bartoli M., Caldwell R.W., Hartnett M.E. Vascular endothelial growth factor in eye disease. Prog. Retin. Eye Res. 2008, 27:331-371.
296. Pepper M.S. Extracellular proteolysis and angiogenesis. Thromb. Haemost. 2001, 86:346-355.
297. Perri S.R., Nalbantoglu J., Annabi B., Koty Z., Lejeune L., Francois M., Di Falco M.R., Beliveau R., Galipeau J. Plasminogen kringle 5-engineered glioma cells block migration of tumor-associated macrophages and suppress tumor vascularization and progression. Cancer Res. 2005, 65:8359-8365.
298. Pillai C.T., Dua H.S., Hossain P. Fine needle diathermy occlusion of corneal vessels. Invest. Ophthalmol. Vis. Sci. 2000, 41:2148-2153.
299. Poliakov A., Cotrina M., Wilkinson D.G. Diverse roles of eph receptors and ephrins in the regulation of cell migration and tissue assembly. Dev. Cell 2004, 7:465-480.
300. Pollina E.A., Legesse-Miller A., Haley E.M., Goodpaster T., Randolph-Habecker J., Coller H.A. Regulating the angiogenic balance in tissues. Cell Cycle 2008, 7:2056-2070.
301. Polverini P.J. The pathophysiology of angiogenesis. Crit. Rev. Oral Biol. Med. 1995, 6:230-247.
302. Poulaki V., Mitsiades N., Kruse F.E., Radetzky S., Iliaki E., Kirchhof B., Joussen A.M. Activin a in the regulation of corneal neovascularization and vascular endothelial growth factor expression. Am. J. Pathol. 2004, 164:1293-1302.
303. Pytowski B., Goldman J., Persaud K., Wu Y., Witte L., Hicklin D.J., Skobe M., Boardman K.C., Swartz M.A. Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody. J. Natl. Cancer Inst. 2005, 97:14-21.
304. Qian C.X., Bahar I., Levinger E., Rootman D. Combined use of superficial keratectomy and subconjunctival bevacizumab injection for corneal neovascularization. Cornea 2008, 27:1090-1092.
305. Ramchandran R., Dhanabal M., Volk R., Waterman M.J., Segal M., Lu H., Knebelmann B., Sukhatme V.P. Antiangiogenic activity of restin, NC10 domain of human collagen XV: comparison to endostatin. Biochem. Biophys. Res. Commun. 1999, 255:735-739.
306. Reed M.J., Corsa A.C., Kudravi S.A., McCormick R.S., Arthur W.T. A deficit in collagenase activity contributes to impaired migration of aged microvascular endothelial cells. J. Cell Biochem. 2000, 77:116-126.
307. Regenfuss B., Bock F., Parthasarathy A., Cursiefen C. Corneal (lymph)angiogenesis - from bedside to bench and back: a tribute to Judah Folkman. Lymphat. Res. Biol. 2008, 6:191-201.
308. Riachy R., Vandewalle B., Moerman E., Belaich S., Lukowiak B., Gmyr V., Muharram G., Kerr Conte J., Pattou F. 1,25-Dihydroxyvitamin D3 protects human pancreatic islets against cytokine-induced apoptosis via down-regulation of the Fas receptor. Apoptosis 2006, 11:151-159.
309. Rissanen T.T., Markkanen J.E., Gruchala M., Heikura T., Puranen A., Kettunen M.I., Kholova I., Kauppinen R.A., Achen M.G., Stacker S.A., Alitalo K., Yla-Herttuala S. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ. Res. 2003, 92:1098-1106.
310. Rogers M.S., Birsner A.E., D'Amato R.J. The mouse cornea micropocket angiogenesis assay. Nat. Protoc. 2007, 2:2545-2550.
311. Ruegg C., Mariotti A. Vascular integrins: pleiotropic adhesion and signaling molecules in vascular homeostasis and angiogenesis. Cell Mol. Life Sci. 2003, 60:1135-1157.
312. Sack R., Sathe S., Beaton A.R., McNamara N., Fleiszig S., Ni M. Protein array characterization of bioactive proteins secreted by immortalized human corneal epithelium in response to pseudomonas constituents. Curr. Eye Res. 2009, 34:92-98.
313. Saghizadeh M., Brown D.J., Castellon R., Chwa M., Huang G.H., Ljubimova J.Y., Rosenberg S., Spirin K.S., Stolitenko R.B., Adachi W., Kinoshita S., Murphy G., Windsor L.J., Kenney M.C., Ljubimov A.V. Overexpression of matrix metalloproteinase-10 and matrix metalloproteinase-3 in human diabetic corneas: a possible mechanism of basement membrane and integrin alterations. Am. J. Pathol. 2001, 158:723-734.
314. Saika S. Yin and yang in cytokine regulation of corneal wound healing: roles of TNF-alpha. Cornea 2007, 26:S70-S74.
315. Saika S., Yamanaka O., Okada Y., Miyamoto T., Kitano A., Flanders K.C., Ohnishi Y., Nakajima Y., Kao W.W., Ikeda K. Effect of overexpression of PPARgamma on the healing process of corneal alkali burn in mice. Am. J. Physiol. Cell Physiol. 2007, 293:C75-C86.
316. Sakamoto T., Ueno H., Sonoda K., Hisatomi T., Shimizu K., Ohashi H., Inomata H. Blockade of TGF-beta by in vivo gene transfer of a soluble TGF-beta type II receptor in the muscle inhibits corneal opacification, edema and angiogenesis. Gene Ther. 2000, 7:1915-1924.
317. Schedin-Weiss S., Richard B., Hjelm R., Olson S.T. Antiangiogenic forms of antithrombin specifically bind to the anticoagulant heparin sequence. Biochemistry 2008, 47:13610-13619.
318. Schermer A., Galvin S., Sun T.T. Differentiation-related expression of a major 64K corneal keratin in vivo and in culture suggests limbal location of corneal epithelial stem cells. J. Cell Biol. 1986, 103:49-62.
319. Schlaeppi J.M., Siemeister G., Weindel K., Schnell C., Wood J. Characterization of a new potent, in vivo neutralizing monoclonal antibody to human vascular endothelial growth factor. J. Cancer Res. Clin. Oncol. 1999, 125:336-342.
320. Schneider M., Buchler P., Giese N., Giese T., Wilting J., Buchler M.W., Friess H. Role of lymphangiogenesis and lymphangiogenic factors during pancreatic cancer progression and lymphatic spread. Int. J. Oncol. 2006, 28:883-890.
321. Schneller M., Vuori K., Ruoslahti E. Alphavbeta3 integrin associates with activated insulin and PDGFbeta receptors and potentiates the biological activity of PDGF. Embo J. 1997, 16:5600-5607.
322. Schönherr E., Sunderkötter C., Schaefer L., Thanos S., Grässel S., Oldberg A., Iozzo R.V., Young M.F., Kresse H. Decorin deficiency leads to impaired angiogenesis in injured mouse cornea. J Vasc. Res. 2004, 41:499-508.
323. Schwartz G.G., Hulka B.S. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res. 1990, 10:1307-1311.
324. Seki T., Yun J., Oh S.P. Arterial endothelium-specific activin receptor-like kinase 1 expression suggests its role in arterialization and vascular remodeling. Circ. Res. 2003, 93:682-689.
325. Seki T., Hong K.H., Yun J., Kim S.J., Oh S.P. Isolation of a regulatory region of activin receptor-like kinase 1 gene sufficient for arterial endothelium-specific expression. Circ. Res. 2004, 94:e72-e77.
326. Sellami D., Abid S., Bouaouaja G., Ben Amor S., Kammoun B., Masmoudi M., Dabbeche K., Boumoud H., Ben Zina Z., Feki J. Epidemiology and risk factors for corneal graft rejection. Transplant. Proc. 2007, 39:2609-2611.
327. Sen T., Moulik S., Dutta A., Choudhury P.R., Banerji A., Das S., Roy M., Chatterjee A. Multifunctional effect of epigallocatechin-3-gallate (EGCG) in downregulation of gelatinase-A (MMP-2) in human breast cancer cell line MCF-7. Life Sci. 2009, 84:194-204.
328. Shao X.J., Chi X.Y. Influence of angiostatin and thalidomide on lymphangiogenesis. Lymphology 2005, 38:146-155.
329. Shen J., Vil M.D., Zhang H., Tonra J.R., Rong L.L., Damoci C., Prewett M., Deevi D.S., Kearney J., Surguladze D., Jimenez X., Iacolina M., Bassi R., Zhou K., Balderes P., Mangalampalli V.R., Loizos N., Ludwig D.L., Zhu Z. An antibody directed against PDGF receptor beta enhances the antitumor and the anti-angiogenic activities of an anti-VEGF receptor 2 antibody. Biochem. Biophys. Res. Commun. 2007, 357:1142-1147.
330. Shepard S.R., Boucher R., Johnston J., Boerner R., Koch G., Madsen J.W., Grella D., Sim B.K., Schrimsher J.L. Large-scale purification of recombinant human angiostatin. Protein Expr. Purif. 2000, 20:216-227.
331. Shi Y.H., Wang Y.X., Bingle L., Gong L.H., Heng W.J., Li Y., Fang W.G. In vitro study of HIF-1 activation and VEGF release by bFGF in the T47D breast cancer cell line under normoxic conditions: involvement of PI-3K/Akt and MEK1/ERK pathways. J. Pathol. 2005, 205:530-536.
332. Shi W., Gao H., Xie L., Wang S. Sustained intraocular rapamycin delivery effectively prevents high-risk corneal allograft rejection and neovascularization in rabbits. Invest. Ophthalmol. Vis. Sci. 2006, 47:3339-3344.
333. Shima D.T., Kuroki M., Deutsch U., Ng Y.S., Adamis A.P., D'Amore P.A. The mouse gene for vascular endothelial growth factor. Genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptional regulatory sequences. J. Biol. Chem. 1996, 271:3877-3883.
334. Shin S.H., Kim J.C., Chang S.I., Lee H., Chung S.I. Recombinant kringle 1-3 of plasminogen inhibits rabbit corneal angiogenesis induced by angiogenin. Cornea 2000, 19:212-217.
335. Simantov R., Febbraio M., Silverstein R.L. The antiangiogenic effect of thrombospondin-2 is mediated by CD36 and modulated by histidine-rich glycoprotein. Matrix Biol. 2005, 24:27-34.
336. Sonmez B., Beden U., Erkan D. Regression of severe corneal stromal neovascularization with topical cyclosporine 0.05% after penetrating keratoplasty for fungal corneal ulcer. Int. Ophthalmol. 2007.
337. Soubrane G., Jerdan J., Karpouzas I., Fayein N.A., Glaser B., Coscas G., Courtois Y., Jeanny J.C. Binding of basic fibroblast growth factor to normal and neovascularized rabbit cornea. Invest. Ophthalmol. Vis. Sci. 1990, 31:323-333.
338. Sounni N.E., Devy L., Hajitou A., Frankenne F., Munaut C., Gilles C., Deroanne C., Thompson E.W., Foidart J.M., Noel A. MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression. Faseb J. 2002, 16:555-564.
339. Sounni N.E., Janssen M., Foidart J.M., Noel A. Membrane type-1 matrix metalloproteinase and TIMP-2 in tumor angiogenesis. Matrix Biol. 2003, 22:55-61.
340. Sounni N.E., Roghi C., Chabottaux V., Janssen M., Munaut C., Maquoi E., Galvez B.G., Gilles C., Frankenne F., Murphy G., Foidart J.M., Noel A. Up-regulation of vascular endothelial growth factor-A by active membrane-type 1 matrix metalloproteinase through activation of Src-tyrosine kinases. J. Biol. Chem. 2004, 279:13564-13574.
341. Spinella F., Garrafa E., Di Castro V., Rosano L., Nicotra M.R., Caruso A., Natali P.G., Bagnato A. Endothelin-1 stimulates lymphatic endothelial cells and lymphatic vessels to grow and invade. Cancer Res. 2009, 69:2669-2676.
342. Srinivasan B.D., Kulkarni P.S. Inhibitors of the arachidonic acid cascade in the management of ocular inflammation. Prog. Clin. Biol. Res. 1989, 312:229-249.
343. Stein E., Lane A.A., Cerretti D.P., Schoecklmann H.O., Schroff A.D., Van Etten R.L., Daniel T.O. Eph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment, and assembly responses. Genes Dev. 1998, 12:667-678.
344. Stephanou A. Role of STAT-1 and STAT-3 in ischaemia/reperfusion injury. J. Cell Mol. Med. 2004, 8:519-525.
345. Sternlicht M.D., Bissell M.J., Werb Z. The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter. Oncogene 2000, 19:1102-1113.
346. Sudhakar A., Boosani C.S. Inhibition of tumor angiogenesis by tumstatin: insights into signaling mechanisms and implications in cancer regression. Pharm. Res. 2008, 25:2731-2739.
347. Sudhakar A., Nyberg P., Keshamouni V.G., Mannam A.P., Li J., Sugimoto H., Cosgrove D., Kalluri R. Human alpha1 type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by alpha1beta1 integrin. J. Clin. Invest. 2005, 115:2801-2810.
348. Sugihara T., Wadhwa R., Kaul S.C., Mitsui Y. A novel alternatively spliced form of murine vascular endothelial growth factor, VEGF 115. J. Biol. Chem. 1998, 273:3033-3038.
349. Sugisaki K., Usui T., Nishiyama N., Jang W.D., Yanagi Y., Yamagami S., Amano S., Kataoka K. Photodynamic therapy for corneal neovascularization using polymeric micelles encapsulating dendrimer porphyrins. Invest. Ophthalmol. Vis. Sci. 2008, 49:894-899.
350. Sun J., Wang D.A., Jain R.K., Carie A., Paquette S., Ennis E., Blaskovich M.A., Baldini L., Coppola D., Hamilton A.D., Sebti S.M. Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors. Oncogene 2005, 24:4701-4709.
351. Sund M., Hamano Y., Sugimoto H., Sudhakar A., Soubasakos M., Yerramalla U., Benjamin L.E., Lawler J., Kieran M., Shah A., Kalluri R. Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:2934-2939.
352. Suzuki T., Sano Y., Kinoshita S. Effects of 1alpha,25-dihydroxyvitamin D3 on Langerhans cell migration and corneal neovascularization in mice. Invest. Ophthalmol. Vis. Sci. 2000, 41:154-158.
353. Suzuki T., Sano Y., Sotozono C., Kinoshita S. Regulatory effects of 1alpha,25-dihydroxyvitamin D(3) on cytokine production by human corneal epithelial cells. Curr. Eye Res. 2000, 20:127-130.
354. Takada Y., Ye X., Simon S. The integrins. Genome Biol. 2007, 8:215.
355. Tallquist M.D., Soriano P., Klinghoffer R.A. Growth factor signaling pathways in vascular development. Oncogene 1999, 18:7917-7932.
356. Tammela T., Petrova T.V., Alitalo K. Molecular lymphangiogenesis: new players. Trends Cell Biol. 2005, 15:434-441.
357. Tammela T., Saaristo A., Lohela M., Morisada T., Tornberg J., Norrmen C., Oike Y., Pajusola K., Thurston G., Suda T., Yla-Herttuala S., Alitalo K. Angiopoietin-1 promotes lymphatic sprouting and hyperplasia. Blood 2005, 105:4642-4648.
358. Tammela T., Zarkada G., Wallgard E., Murtomaki A., Suchting S., Wirzenius M., Waltari M., Hellstrom M., Schomber T., Peltonen R., Freitas C., Duarte A., Isoniemi H., Laakkonen P., Christofori G., Yla-Herttuala S., Shibuya M., Pytowski B., Eichmann A., Betsholtz C., Alitalo K. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 2008, 454:656-660.
359. Tao Y., Bazan H.E., Bazan N.G. Platelet-activating factor induces the expression of metalloproteinases-1 and -9, but not -2 or -3, in the corneal epithelium. Invest. Ophthalmol. Vis. Sci. 1995, 36:345-354.
360. Tarui T., Miles L.A., Takada Y. Specific interaction of angiostatin with integrin alpha(v)beta(3) in endothelial cells. J. Biol. Chem. 2001, 276:39562-39568.
361. Tawe W., Pearlman E., Unnasch T.R., Lustigman S. Angiogenic activity of Onchocerca volvulus recombinant proteins similar to vespid venom antigen 5. Mol. Biochem. Parasitol. 2000, 109:91-99.
362. ten Dijke P., Hill C.S. New insights into TGF-beta-Smad signalling. Trends Biochem. Sci. 2004, 29:265-273.
363. Thomas M., Augustin H.G. The role of the angiopoietins in vascular morphogenesis. Angiogenesis 2009.
364. Tomasek J.J., Halliday N.L., Updike D.L., Ahern-Moore J.S., Vu T.K., Liu R.W., Howard E.W. Gelatinase A activation is regulated by the organization of the polymerized actin cytoskeleton. J. Biol. Chem. 1997, 272:7482-7487.
365. Tomono Y., Naito I., Ando K., Yonezawa T., Sado Y., Hirakawa S., Arata J., Okigaki T., Ninomiya Y. Epitope-defined monoclonal antibodies against multiplexin collagens demonstrate that type XV and XVIII collagens are expressed in specialized basement membranes. Cell Struct. Funct. 2002, 27:9-20.
366. Tsai R.J., Tseng S.C. Human allograft limbal transplantation for corneal surface reconstruction. Cornea 1994, 13:389-400.
367. Tseng S.C. Concept and application of limbal stem cells. Eye 1989, 3(Pt 2):141-157.
368. Turner A.N., Rees A.J. Goodpasture's disease and Alport's syndromes. Annu. Rev. Med. 1996, 47:377-386.
369. Udayakumar T.S., Nagle R.B., Bowden G.T. Fibroblast growth factor-1 transcriptionally induces membrane type-1 matrix metalloproteinase expression in prostate carcinoma cell line. Prostate 2004, 58:66-75.
370. Ueda T., Ueda T., Fukuda S., Browne R., Jenis E., Spengler R., Chou R., Buch P., Aljada A., Dandona P., Sasisekharan R., Dorey C.K., Armstrong D. Lipid hydroperoxide-induced tumor necrosis factor (TNF)-alpha, vascular endothelial growth factor and neovascularization in the rabbit cornea: effect of TNF inhibition. Angiogenesis 1998, 1:174-184.
371. Ueda E., Ozerdem U., Chen Y.H., Yao M., Huang K.T., Sun H., Martins-Green M., Bartolini P., Walker A.M. A molecular mimic demonstrates that phosphorylated human prolactin is a potent anti-angiogenic hormone. Endocr. Relat. Cancer 2006, 13:95-111.
372. Uy H.S., Chan P.S., Ang R.E. Topical bevacizumab and ocular surface neovascularization in patients with Stevens-Johnson syndrome. Cornea 2008, 27:70-73.
373. Van Buskirk E.M. The anatomy of the limbus. Eye 1989, 3(Pt 2):101-108.
374. Vazquez F., Hastings G., Ortega M.A., Lane T.F., Oikemus S., Lombardo M., Iruela-Arispe M.L. METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity. J. Biol. Chem. 1999, 274:23349-23357.
375. Vlahakis N.E., Young B.A., Atakilit A., Hawkridge A.E., Issaka R.B., Boudreau N., Sheppard D. Integrin alpha9beta1 directly binds to vascular endothelial growth factor (VEGF)-A and contributes to VEGF-A-induced angiogenesis. J. Biol. Chem. 2007, 282:15187-15196.
376. Vogten J.M., Reijerkerk A., Meijers J.C., Voest E.E., Borel Rinkes I.H., Gebbink M.F. The role of the fibrinolytic system in corneal angiogenesis. Angiogenesis 2003, 6:311-316.
377. Wallace G.R., John Curnow S., Wloka K., Salmon M., Murray P.I. The role of chemokines and their receptors in ocular disease. Prog. Retin. Eye Res. 2004, 23:435-448.
378. Wang H.U., Chen Z.F., Anderson D.J. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 1998, 93:741-753.
379. Wang J.F., Zhang X.F., Groopman J.E. Stimulation of beta 1 integrin induces tyrosine phosphorylation of vascular endothelial growth factor receptor-3 and modulates cell migration. J. Biol. Chem. 2001, 276:41950-41957.
380. Wang K., Mahalingam G., Hoover S.E., Mont E.K., Holland S.M., Cohen J.I., Straus S.E. Diverse herpes simplex virus type 1 thymidine kinase mutants in individual human neurons and ganglia. J. Virol. 2007, 81:6817-6826.
381. Weis S.M., Lindquist J.N., Barnes L.A., Lutu-Fuga K.M., Cui J., Wood M.R., Cheresh D.A. Cooperation between VEGF and beta3 integrin during cardiac vascular development. Blood 2007, 109:1962-1970.
382. Wen W., Moses M.A., Wiederschain D., Arbiser J.L., Folkman J. The generation of endostatin is mediated by elastase. Cancer Res. 1999, 59:6052-6056.
383. Wertheim M.S., Cook S.D., Knox-Cartwright N.E., Van D.L., Tole D.M. Electrolysis-needle cauterization of corneal vessels in patients with lipid keratopathy. Cornea 2007, 26:230-231.
384. Wheeler-Jones C., Abu-Ghazaleh R., Cospedal R., Houliston R.A., Martin J., Zachary I. Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44 mitogen-activated protein kinase. FEBS Lett. 1997, 420:28-32.
385. Whitehurst B., Flister M.J., Bagaitkar J., Volk L., Bivens C.M., Pickett B., Castro-Rivera E., Brekken R.A., Gerard R.D., Ran S. Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model. Int. J. Cancer 2007, 121:2181-2191.
386. WHO Trachoma 2009, (accessed 2.05.09). http://wwwwhoint/blindness/causes/trachoma/en/indexhtml.
387. Wiberg C., Hedbom E., Khairullina A., Lamande S.R., Oldberg A., Timpl R., Morgelin M., Heinegard D. Biglycan and decorin bind close to the n-terminal region of the collagen VI triple helix. J. Biol. Chem. 2001, 276:18947-18952.
388. Wigle J.T., Harvey N., Detmar M., Lagutina I., Grosveld G., Gunn M.D., Jackson D.G., Oliver G. An essential role for Prox1 in the induction of the lymphatic endothelial cell phenotype. Embo J. 2002, 21:1505-1513.
389. Witmer A.N., Vrensen G.F., Van Noorden C.J., Schlingemann R.O. Vascular endothelial growth factors and angiogenesis in eye disease. Prog. Retin. Eye Res. 2003, 22:1-29.
390. Woodall B.P., Nystrom A., Iozzo R.A., Eble J.A., Niland S., Krieg T., Eckes B., Pozzi A., Iozzo R.V. Integrin alpha2beta1 is the required receptor for endorepellin angiostatic activity. J. Biol. Chem. 2008, 283:2335-2343.
391. Wu P.C., Yang L.C., Kuo H.K., Huang C.C., Tsai C.L., Lin P.R., Wu P.C., Shin S.J., Tai M.H. Inhibition of corneal angiogenesis by local application of vasostatin. Mol. Vis. 2005, 11:28-35.
392. Wu P.C., Kuo H.K., Tai M.H., Shin S.J. Topical bevacizumab eyedrops for limbal-conjunctival neovascularization in impending recurrent pterygium. Cornea 2009, 28:103-104.
393. Wulfing P., Kersting C., Buerger H., Mattsson B., Mesters R., Gustmann C., Hinrichs B., Tio J., Bocker W., Kiesel L. Expression patterns of angiogenic and lymphangiogenic factors in ductal breast carcinoma in situ. Br. J. Cancer 2005, 92:1720-1728.
394. Xie L., Palmsten K., MacDonald B., Kieran M.W., Potenta S., Vong S., Kalluri R. Basement membrane derived fibulin-1 and fibulin-5 function as angiogenesis inhibitors and suppress tumor growth. Exp. Biol. Med. (Maywood) 2008, 233:155-162.
395. Xue M.L., Zhu H., Thakur A., Willcox M. 1 alpha,25-Dihydroxyvitamin D3 inhibits pro-inflammatory cytokine and chemokine expression in human corneal epithelial cells colonized with Pseudomonas aeruginosa. Immunol. Cell Biol. 2002, 80:340-345.
396. Yamada M., Kawai M., Kawai Y., Mashima Y. The effect of selective cyclooxygenase-2 inhibitor on corneal angiogenesis in the rat. Curr. Eye Res. 1999, 19:300-304.
397. Yamada N., Yanai R., Kawamoto K., Nagano T., Nakamura M., Inui M., Nishida T. Promotion of corneal epithelial wound healing by a tetrapeptide (SSSR) derived from IGF-1. Invest. Ophthalmol. Vis. Sci. 2006, 47:3286-3292.
398. Yamamoto T., Terada N., Nishizawa Y., Petrow V. Angiostatic activities of medroxyprogesterone acetate and its analogues. Int. J. Cancer 1994, 56:393-399.
399. Yan W., Bentley B., Shao R. Distinct angiogenic mediators are required for basic fibroblast growth factor - and vascular endothelial growth factor - induced angiogenesis: the role of cytoplasmic tyrosine kinase c-Abl in tumor angiogenesis. Mol. Biol. Cell 2008, 19:2278-2288.
400. Yancopoulos G.D., Davis S., Gale N.W., Rudge J.S., Wiegand S.J., Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000, 407:242-248.
401. Ye H.Q., Azar D.T. Expression of gelatinases A and B, and TIMPs 1 and 2 during corneal wound healing. Invest. Ophthalmol. Vis. Sci. 1998, 39:913-921.
402. Ye H.Q., Maeda M., Yu F.S., Azar D.T. Differential expression of MT1-MMP (MMP-14) and collagenase III (MMP-13) genes in normal and wounded rat corneas. Invest. Ophthalmol. Vis. Sci. 2000, 41:2894-2899.
403. Yoeruek E., Ziemssen F., Henke-Fahle S., Tatar O., Tura A., Grisanti S., Bartz-Schmidt K.U., Szurman P. Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn. Acta Ophthalmol. 2008, 86:322-328.
404. Yoon K.C., Ahn K.Y., Lee S.E., Kim K.K., Im S.K., Oh H.J., Jeong I.Y., Park S.W., Park Y.G., Nah H.J., Im W.B. Experimental inhibition of corneal neovascularization by photodynamic therapy with verteporfin. Curr. Eye Res. 2006, 31:215-224.
405. Yoon K.C., You I.C., Kang I.S., Im S.K., Ahn J.K., Park Y.G., Ahn K.Y. Photodynamic therapy with verteporfin for corneal neovascularization. Am. J. Ophthalmol. 2007, 144:390-395.
406. Yoshida S., Ono M., Shono T., Izumi H., Ishibashi T., Suzuki H., Kuwano M. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol. Cell Biol. 1997, 17:4015-4023.
407. Yoshida S., Yoshida A., Matsui H., Takada Y., Ishibashi T. Involvement of macrophage chemotactic protein-1 and interleukin-1beta during inflammatory but not basic fibroblast growth factor-dependent neovascularization in the mouse cornea. Lab. Invest. 2003, 83:927-938.
408. Yu C.Q., Zhang M., Matis K.I., Kim C., Rosenblatt M.I. Vascular endothelial growth factor mediates corneal nerve repair. Invest. Ophthalmol. Vis. Sci. 2008, 49:3870-3878.
409. Zawieja D. Lymphatic biology and the microcirculation: past, present and future. Microcirculation 2005, 12:141-150.
410. Zeng L., Xiao Q., Margariti A., Zhang Z., Zampetaki A., Patel S., Capogrossi M.C., Hu Y., Xu Q. HDAC3 is crucial in shear- and VEGF-induced stem cell differentiation toward endothelial cells. J. Cell Biol. 2006, 174:1059-1069.
411. Zhang H.T., Scott P.A., Morbidelli L., Peak S., Moore J., Turley H., Harris A.L., Ziche M., Bicknell R. The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo. Br. J. Cancer 2000, 83:63-68.
412. Zhang H., Li C., Baciu P.C. Expression of integrins and MMPs during alkaline-burn-induced corneal angiogenesis. Invest. Ophthalmol. Vis. Sci. 2002, 43:955-962.
413. Zhang W., Ran S., Sambade M., Huang X., Thorpe P.E. A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model. Angiogenesis 2002, 5:35-44.
414. Zheng M., Deshpande S., Lee S., Ferrara N., Rouse B.T. Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis. J. Virol. 2001, 75:9828-9835.
415. Zhou Z., Apte S.S., Soininen R., Cao R., Baaklini G.Y., Rauser R.W., Wang J., Cao Y., Tryggvason K. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:4052-4057.